Nutri Pharmaceuticals Research, Inc. (Pink Sheets: NRPR) recently announced First Quarter 2007 results of approximately $500,000 in revenues and $132,000 in earnings. The results reflect new marketing strategies, introduction of unique products to different markets and growing popularity of their powders for increasing manufacturing demands. These factors should continue to allow for significantly higher sales and earnings in future quarters with a large increase in its stock price. Nutri Pharmaceuticals Research, Inc., www.o2pus.com, provides a wide range of powdered oils for functional food, food supplement, pharmaceutical, cosmetic, pet food and animal feed applications. The company is one of a select few to be awarded the prestigious Nutrition Business Journal "Product Merit Award" for its patent-pending O2P� Powderization process. The patent-pending process converts most edible oils, gels, pastes and other viscous fluids into a free-flowing powder without affecting the isomeric structure, fatty acid profile, color, taste or aroma of the base oil or fluids. Along with other exciting products the company produces, possibly the most exciting and potentially large sales potentials exist in producing oil to powder from fish oil and flaxseeds when added to food products increases the omega 3 fats in the body which is currently one�of the fastest growing areas of the health food industry. The company is a leader in this area and with other products could provide large orders and significant sales and earnings in future years. Forward-looking statements All statements contained in this Press Release, other than statements of historical facts, that address future activities, events or developments are forward-looking statements, including, but not limited to, statements containing the words "believe," "anticipate," "expect" and words of similar import. These statements are based on certain assumptions and analyses made by us in light of our experience and our assessment of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances. However, whether actual results will conform to the expectations and predictions of management is subject to a number of risks and uncertainties that may cause actual results to differ materially. Such risks include, among others, the following: international, national and local general economic and market conditions: our ability to sustain, manage or forecast our growth; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; and other factors referenced in this and previous disclosures. Consequently, all of the forward-looking statements made in this Press Release are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by management will be realized or, even if substantially realized, that they will have the expected results or consequences to or effects on our business operations.
Nutri Pharmaceuticals Re... (PK) (USOTC:NRPR)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Nutri Pharmaceuticals Re... (PK) Charts.
Nutri Pharmaceuticals Re... (PK) (USOTC:NRPR)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Nutri Pharmaceuticals Re... (PK) Charts.